TODD STRATEGY GROUP

Lobbying for EXELIXIS, INC. · Biotechnology company.

Filing 4th Quarter - Report

4th Quarter (Oct 1 - Dec 31) 2025 · California · House · Senate · $50,000.00 income · posted Jan 20, 2026

Lobbying activity 3

Health Issues

Policy to advance pharmaceutical research and development. 340B.

Medicare/Medicaid

Implementation of Inflation Reduction Act of 2022.

Intellectual property.

Source: federal Lobbying Disclosure Act filing. Bills are parsed from the activity descriptions.